Anzeige
Mehr »
Donnerstag, 08.01.2026 - Börsentäglich über 12.000 News
Steht diese NASDAQ-Biotech-Aktie jetzt vor einer seltenen Kaufgelegenheit?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0Q2S4 | ISIN: US1920051067 | Ticker-Symbol: 4QK
Tradegate
07.01.26 | 18:31
1,476 Euro
+1,65 % +0,024
1-Jahres-Chart
CODEXIS INC Chart 1 Jahr
5-Tage-Chart
CODEXIS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,4371,47420:47
1,4371,47420:20

Aktuelle News zur CODEXIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiCodexis Expands Reach of the ECO Synthesis Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics170REDWOOD CITY, Calif., Jan. 7, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing and Axolabs...
► Artikel lesen
10.11.25Codexis, Inc.: Codexis Announces Signing of Lease for GMP Manufacturing Facility13
CODEXIS Aktie jetzt für 0€ handeln
07.11.25Codexis signals transformation to full-service manufacturing innovator with ECO Synthesis platform and expects 2025 revenue at or above top end of guidance17
06.11.25Codexis, Inc.: Codexis Reports Third Quarter 2025 Financial Results229Announces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended through 2027 REDWOOD CITY, Calif.,...
► Artikel lesen
06.11.25CODEXIS, INC. - 10-Q, Quarterly Report-
06.11.25CODEXIS, INC. - 8-K, Current Report-
29.10.25Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis Manufacturing Platform for Therapeutic siRNA Manufacturing392REDWOOD CITY, Calif., Oct. 29, 2025 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and...
► Artikel lesen
23.10.25Codexis, Inc.: Codexis to Report Third Quarter 2025 Financial Results on November 615
19.08.25Benchmark reiterates Hold rating on Codexis stock after Q2 results6
19.08.25Benchmark bestätigt "Halten"-Einstufung für Codexis nach Q2-Zahlen6
14.08.25Stifel maintains Buy rating on Codexis stock amid strong business outlook14
14.08.25Cantor Fitzgerald bestätigt Codexis mit "Overweight" und Kursziel von 11 US-Dollar15
14.08.25Cantor Fitzgerald reiterates Overweight rating on Codexis stock, maintains $11 price target4
14.08.25Codexis reiterates $64M-$68M 2025 revenue guidance while exploring ECO Synthesis expansion3
13.08.25CODEXIS, INC. - S-8, Securities to be offered to employees in employee benefit plans3
12.08.25A Look at Codexis' Upcoming Earnings Report3
07.03.25Codexis, Inc.: Codexis Announces New Employment Inducement Grants285REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced...
► Artikel lesen
14.02.25Codexis, Inc.: Codexis Announces New Employment Inducement Grants329REDWOOD CITY, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced...
► Artikel lesen
10.01.25Codexis, Inc.: Codexis Announces New Employment Inducement Grants341REDWOOD CITY, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1